drugset / Trial / NCT05979896

Chemoprevention Efficacy Study Nigeria

NCT05979896

Phase 4 Unknown 800 enrolled Malaria Consortium
NaSingle-groupOpen-labelPrevention

Summary

The study aims to assess the chemoprevention efficacy of Sulfadoxine-Pyrimethamine and Amodiaquine (SPAQ) used in standard age-based dosing regimens used in Seasonal Malaria Chemoprevention (SMC) and SPAQ resistance marker prevalences and assocations among children 3 - 59 months in Sokoto and Kwara States, Nigeria.

Timeline

Start
2023-07-28
Primary completion
2023-09-15
Completion
2024-05-15

Drugs

EvaluationDrugModalityDoseRoute
Subject amodiaquine Other / unclassified
Subject pyrimethamine Small molecule Oral
Subject sulfadoxine Small molecule Oral

Indications